share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/15 08:05
Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has announced a one-for-one hundred reverse stock split of its common stock and warrants. This corporate action was previously reported in a Form 8-K filed on May 10, 2024, and the Certificate of Amendment was filed with the Secretary of State of Texas on May 6, 2024. The reverse stock split will result in every one hundred shares of the pre-split issued and outstanding common stock being automatically converted into one post-split share. Fractional shares will be rounded up. The reverse stock split will take effect at the market open on May 17, 2024, with the common stock trading under the new CUSIP number 42254E302. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively. Adjustments will also be made to the company's outstanding warrants, with the exercise price per share of common stock attributable to the public warrants increasing to $425.00 post-split. The CUSIP for the public warrants will remain unchanged.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has announced a one-for-one hundred reverse stock split of its common stock and warrants. This corporate action was previously reported in a Form 8-K filed on May 10, 2024, and the Certificate of Amendment was filed with the Secretary of State of Texas on May 6, 2024. The reverse stock split will result in every one hundred shares of the pre-split issued and outstanding common stock being automatically converted into one post-split share. Fractional shares will be rounded up. The reverse stock split will take effect at the market open on May 17, 2024, with the common stock trading under the new CUSIP number 42254E302. The trading symbols for the common stock and public warrants will remain 'HSCS' and 'HSCSW' respectively. Adjustments will also be made to the company's outstanding warrants, with the exercise price per share of common stock attributable to the public warrants increasing to $425.00 post-split. The CUSIP for the public warrants will remain unchanged.
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 宣布对其普通股和认股权证进行一比一的反向股票拆分。该公司诉讼此前曾在2024年5月10日提交的8-K表格中报告，修正证书于2024年5月6日提交给德克萨斯州国务卿。反向股票拆分将导致拆分前已发行和流通的普通股中每100股自动转换为拆分后的一股。零星股票将四舍五入。反向股票拆分将在2024年5月17日开盘时生效，普通股将以新的CUSIP编号 42254E302 进行交易。普通股和公开认股权证的交易代码将分别保持为 “HSCS” 和 “HSCSW”。还将对公司的未偿认股权证进行调整，公开认股权证所占普通股的每股行使价提高至425.00美元。公开认股权证的CUSIP将保持不变。
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 宣布对其普通股和认股权证进行一比一的反向股票拆分。该公司诉讼此前曾在2024年5月10日提交的8-K表格中报告，修正证书于2024年5月6日提交给德克萨斯州国务卿。反向股票拆分将导致拆分前已发行和流通的普通股中每100股自动转换为拆分后的一股。零星股票将四舍五入。反向股票拆分将在2024年5月17日开盘时生效，普通股将以新的CUSIP编号 42254E302 进行交易。普通股和公开认股权证的交易代码将分别保持为 “HSCS” 和 “HSCSW”。还将对公司的未偿认股权证进行调整，公开认股权证所占普通股的每股行使价提高至425.00美元。公开认股权证的CUSIP将保持不变。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息